Five percent of the adults in our survey gave the most honest answer available when asked where they would go for a newer depression treatment: they would not know where to start.
Judging by the rest of our data, that figure is low. Among the 443 people who answered, 73 percent said Spravato was a name they had never once come across, and 21 percent more knew the name and nothing else. Spravato is the esketamine nasal spray with FDA approval for depression that has not budged under standard medication. People who do reach it are usually walked there by somebody.
This guide is the walk. It assumes ordinary antidepressants have not done enough for you or someone you love.
Step one: start where almost everyone else starts
We asked people where they would turn first, and a clear majority of our respondents, 56 percent, picked the family doctor. The next most common choice, at 23 percent, was a psychiatrist or other mental health professional, while going online alone drew 12 percent.
That majority instinct is sound, and not because of etiquette. The approved spray runs through a prescriber and a certified site, and eligibility hinges on a written record of earlier medication trials. The doctor you already see holds that record. Starting somewhere else usually means rebuilding it.
No regular doctor? Any prescriber who can pull up your chart works: a psychiatric nurse practitioner, a federally qualified clinic, or the behavioral health intake line at a regional hospital.
Step two: find out which door you are looking for
- A certified esketamine center can give the FDA-approved spray under its restricted program, with a clinician in the room and a watch period after every dose.
- An infusion clinic running IV ketamine for mood problems is using an approved drug off label. That is legal and common, but it rests on different regulatory ground and usually a different way of paying.
- An online service that prescribes ketamine to take at home is a third model, farther from monitored care, and deserves hard questions before you sign up.
Pick your target before dialing, because asking for "ketamine treatment" routes you to whatever the person on the phone happens to run.
Step three: verify a clinic the boring way
Search results here are heavily advertised, so read the first page as a list of businesses, not a quality ranking.
- Who prescribes? Get the name and license of the responsible physician or advanced practice clinician, then check it with your state licensing board.
- Is the site certified for the approved product, if that is what you want? Ask plainly, and ask what a session looks like from arrival to discharge.
- What medical monitoring is on hand, and what is the plan for a spike in blood pressure or a rough session?
- Do they want a referral, records, or proof of earlier medication trials? A clinic that wants none of that deserves a second look.
- Who manages your psychiatric care over time, and will they talk to your current prescriber and therapist?
Step four: settle the money before the schedule
When our respondents ranked what matters most in a provider, coverage ran away with it, showing up among the top two picks of 85 percent. Nearness to home came second at 43 percent. Quick results drew 24 percent and FDA approval 27 percent; discretion drew 11 percent, and 10 percent wanted a practice that specializes in veterans or first responders.
They also said how much hassle coverage is worth. We offered a trade: insured care with extra hoops, or paying out of pocket for a faster, simpler start. Half, 51 percent, took the hoops; 23 percent would pay and skip the wait; the remaining 26 percent could not decide.
So run the coverage errand properly. Ring the member services line your plan lists and ask five things: is esketamine covered, is prior authorization needed, what proof of earlier treatment failures do they want, must the site be in network, and are the drug and the visit billed apart. Note the call reference number. If you are denied, ask how appeals work; first-round denials are routine for specialty care. Once you know what your plan says, Brain Recovery Centers keeps a straightforward page on Spravato treatment you can compare against it.
Our sample's payer mix shows this is not only a commercial-insurance story. Respondents checked a commercial plan 39 percent of the time and Medicaid 37 percent; Medicare followed at 23, the uninsured made up 9, and TRICARE 5 percent. Rules differ sharply across those, so ask about your exact plan.
Step five: match the format to your actual life
On format, an in-person clinic was the choice of 44 percent of respondents. Home telehealth pulled 22 percent, a clinic-first blend that shifts home later pulled 23, and the leftover 11 percent had no preference.
That choice is more than taste. Monitored in-clinic care means repeat appointments, a wait afterward, and a driver. Before you commit, count the mileage, the hours off work, the childcare, and whether a ride exists for every visit. A plan that falls apart in week three is worse than an honest one built in week one.
Step six: keep the rest of your care intact
Newer treatments get added to a plan, not swapped in for it. Keep your therapist. Stay on prescribed medication unless your prescriber changes it. Track your mood with a standard rating scale so progress is measured, and bring that record to each visit.
Helping someone else? Take the logistics: calls, insurance notes, driving. People rarely stall on willingness. They stall on the phone calls.
A necessary caution
This guide is about finding your way through a system, not a recommendation of any treatment or clinic, and not medical advice. Esketamine is not for everyone, its side effects are real, and eligibility is a clinical call you make with someone who knows your history.
Thoughts of suicide are not something to hold until your next appointment. Reach 988 by call or text and a Lifeline counselor answers whatever the hour, free and in confidence. Help exists tonight, before any step above.
Methodology
Numbers above come from our own first-party survey, which the publisher commissioned and paid for. Pollfish drew 443 respondents from its consumer panel, all 18 to 64 and all living in one of ten Midwest states; fieldwork closed June 23, 2026. Everyone consented before answering. Questions that let people choose several answers produce totals above 100. These results reflect the panel after its final validation.